Physician profile
Daniel R Douce
NPI 1851541353
$825.61
in general payments reported to CMS, 2019-2025
20 companies · $249 in 2025
The $249 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2022: $33.57 · 2023: $383 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $446 · Education: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $446.07 |
| Education | $185.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $169.19 | 2023-2025 | |
| Genentech USA, INC. | $103.99 | 2023-2025 | Polivy, Columvi, Lunsumio |
| Gilead Sciences, INC. | $93.00 | 2023 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $87.54 | 2019-2025 | Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $69.81 | 2019-2025 | Opdivo |
| Janssen Biotech, INC. | $45.48 | 2019-2023 | Darzalex |
| Amgen INC. | $27.55 | 2023 | Kyprolis, Blincyto |
| Celgene Corporation | $26.20 | 2025 | Opdivo |
| Astellas Pharma US INC | $24.49 | 2023 | Xtandi |
| Stemline Therapeutics INC. | $23.97 | 2023 | Orserdu |
| Kite Pharma, INC. | $19.73 | 2023 | Yescarta |
| Taiho Oncology, INC. | $19.45 | 2019 | |
| Pharmacosmos Therapeutics INC. | $18.86 | 2023 | Monoferric |
| Emd Serono, INC. | $17.54 | 2019 | |
| Verity Pharmaceuticals INC. | $16.43 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $13.38 | 2023 | Tivdak |
| Lilly USA, LLC | $13.30 | 2019 | |
| Genzyme Corporation | $12.12 | 2019 | |
| Abbvie INC. | $12.11 | 2019 | |
| Pfizer INC. | $11.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Douce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.